Related Experiment Video
Updated: Jun 29, 2026
10:29
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
Published on: November 12, 2010
Does neurotropin-3 have a therapeutic implication in major depression?
Chi-Un Pae1, David M Marks, Changsu Han
1Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea. pae@catholic.ac.kr
The International Journal of Neuroscience
|October 15, 2008
Summary
Neurotropin-3 (NT3) shows potential as a novel antidepressant by regulating neuroprotection and synaptic plasticity. Further research is warranted to explore its therapeutic implications for major depression.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Major depression treatment faces challenges with incomplete functional recovery in some patients.
- Emerging evidence links depression pathogenesis to neurotransmitters beyond serotonin, norepinephrine, and dopamine.
- Alterations in neuroprotection and synaptic plasticity are associated with depression.
Purpose of the Study:
- To explore the therapeutic potential of Neurotropin-3 (NT3) for major depression.
- To investigate NT3's role in neuroprotection, synaptic plasticity, and neurotransmission.
- To evaluate NT3 as a novel antidepressant target.
Main Methods:
- Review of existing literature on NT3, BDNF, and depression.
- Analysis of NT3's effects on neuronal survival, synaptic plasticity, and neurogenesis.
- Examination of animal model studies demonstrating NT3's antidepressant effects.
Main Results:
- NT3 regulates neuronal survival, synaptic plasticity, and neurotransmission, particularly in the hippocampus.
- NT3 infusion increases brain-derived neurotrophic factor (BDNF) mRNA expression and mimics BDNF effects.
- Animal studies indicate NT3 possesses antidepressant properties and modulates serotonin and noradrenaline.
Conclusions:
- NT3 presents a promising novel therapeutic mechanism for depression.
- NT3's influence on neuroprotection and synaptic plasticity warrants further investigation.
- NT3 may contribute to the development of more effective antidepressant agents.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:27Depressive Disorders: Etiology
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
01:14Brain Imaging
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).